Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes von Estrada-Bernal, Adriana, Le, Anh T, Doak, Andrea E, Tirunagaru, Vijaya G, Silva, Shevan, Bull, Matthew R, Smaill, Jeff B, Patterson, Adam V, Kim, Chul, Liu, Stephen V, Doebele, Robert C

Volltext

Milademetan is a highly potent MDM2 inhibitor in Merkel cell carcinoma von Ananthapadmanabhan, Varsha, Frost, Thomas C, Soroko, Kara M, Knott, Aine, Magliozzi, Brianna J, Gokhale, Prafulla C, Tirunagaru, Vijaya G, Doebele, Robert C, DeCaprio, James A

Volltext

A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas von Gounder, Mrinal M, Bauer, Todd M, Schwartz, Gary K, Weise, Amy M, LoRusso, Patricia, Kumar, Prasanna, Tao, Ben, Hong, Ying, Patel, Parul, Lu, Yasong, Lesegretain, Arnaud, Tirunagaru, Vijaya G, Xu, Feng, Doebele, Robert C, Hong, David S

Volltext

GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers von Bianco, Gaia, Coto-Llerena, Mairene, Gallon, John, Kancherla, Venkatesh, Taha-Mehlitz, Stephanie, Marinucci, Mattia, Konantz, Martina, Srivatsa, Sumana, Montazeri, Hesam, Panebianco, Federica, Tirunagaru, Vijaya G., De Menna, Marta, Paradiso, Viola, Ercan, Caner, Dahmani, Ahmed, Montaudon, Elodie, Beerenwinkel, Niko, Kruithof-de Julio, Marianna, Terracciano, Luigi M., Lengerke, Claudia, Jeselsohn, Rinath M., Doebele, Robert C., Bidard, François-Clément, Marangoni, Elisabetta, Ng, Charlotte K. Y., Piscuoglio, Salvatore

Volltext

Discovery of Tetralones as Potent and Selective Inhibitors of Acyl-CoA:Diacylglycerol Acyltransferase 1 von Cheung, Mui, Tangirala, Raghuram S, Bethi, Sridhar R, Joshi, Hemant V, Ariazi, Jennifer L, Tirunagaru, Vijaya G, Kumar, Sanjay

Volltext

Author Correction: GATA3 and MDM2 are synthetic lethal in estrogen receptor-positive breast cancers von Bianco, Gaia, Coto-Llerena, Mairene, Gallon, John, Kancherla, Venkatesh, Taha-Mehlitz, Stephanie, Marinucci, Mattia, Konantz, Martina, Srivatsa, Sumana, Montazeri, Hesam, Panebianco, Federica, Tirunagaru, Vijaya G., De Menna, Marta, Paradiso, Viola, Ercan, Caner, Dahmani, Ahmed, Montaudon, Elodie, Beerenwinkel, Niko, Kruithof-de Julio, Marianna, Terracciano, Luigi M., Lengerke, Claudia, Jeselsohn, Rinath M., Doebele, Robert C., Bidard, François-Clément, Marangoni, Elisabetta, Ng, Charlotte K. Y., Piscuoglio, Salvatore

Volltext

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification von Elkrief, Arielle, Odintsov, Igor, Markov, Vladimir, Caeser, Rebecca, Sobczuk, Pawel, Tischfield, Sam E., Bhanot, Umesh, Vanderbilt, Chad M., Cheng, Emily H., Drilon, Alexander, Riely, Gregory J., Lockwood, William W., de Stanchina, Elisa, Tirunagaru, Vijaya G., Doebele, Robert C., Quintanal-Villalonga, Álvaro, Rudin, Charles M., Somwar, Romel, Ladanyi, Marc

Volltext

Abstract 4025: STEAP4 ISH and IHC diagnostics for Tarloxotinib activation in EGFR/HER2 mutant cancers von Yu, Hui, Silva, Shevan, Estrada-Bernal, Adriana, Rivard, Chris, Hirsch, Fred, Abbatista, Maria, Smaill, Jeff, Doebele, Robert C., Patterson, Adam, Vellanki, Avanish, Tirunagaru, Vijaya G.

Volltext

Abstract P210: MDM2 gene amplification as a predictive biomarker for the MDM2 inhibitor milademetan von Tirunagaru, Vijaya G., Gounder, Mrinal M., Kumar, Prasanna R., Hong, David S., Doebele, Robert C.

Volltext

Using CDKN2A loss in the context of wildtype TP53 to predict sensitivity for the MDM2 inhibitor milademetan von Tirunagaru, Vijaya G, Xu, Feng, Hinz, Trista, Heasley, Lynn, Bryce, Richard, Vellanki, Avanish, Ku, Nora, Doebele, Robert Charles

Volltext

Abstract P215: The MDM2 inhibitor milademetan induces synthetic lethality in GATA3 mutant, ER positive breast cancer von Tirunagaru, Vijaya G., Bianco, Gaia, Ng, Charlotte K. Y., Marangoni, Elisabetta, Piscuoglio, Salvatore, Bidard, François-Clément, Doebele, Robert C.

Volltext

Abstract 1174: Exploration of MDM2 gene amplification, co-mutation status, and prognosis in solid tumors von Tirunagaru, Vijaya G., Xu, Feng, Doebele, Robert C.

Volltext

Abstract 2200: Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors von Suda, Kenichi, Nishino, Masaya, Koga, Takamasa, Fujino, Toshio, Kobayashi, Yoshihisa, Mitsudomi, Tetsuya, Vellanki, Avanish, Tirunagaru, Vijaya G.

Volltext

Abstract 2202: Tarloxotinib exhibits potent activity in NRG1 fusion and rearranged cancers von Tirunagaru, Vijaya G., Estrada-Bernal, Adriana, Yu, Hui, Rivard, Chris, Hirsch, Fred, Bull, Matthew, Abbatista, Maria, Smaill, Jeff, Patterson, Adam V., Doebele, Robert C., Vellanki, Avanish

Volltext

Abstract 2643: Discovery and characterization of a selective TrkA inhibitor for the treatment of TrkA-driven cancers von Tirunagaru, Vijaya G., Nagaswamy, Kumaragurubaran, Mitra, Sayan, Maddi, Srinivas, Adluri, Ram Sudheer, Joshi, Hemant, Gupta, Jang B.

Volltext

Abstract 373: Discovery of selective PI3Kb inhibitors for PTEN-deficient tumors and other indications von Chowdhury, Arnab R., Athisayamani, Jeyaraj D., Mitra, Sayan, Maddi, Srinivas, Adluri, Ram Sudheer, Bethi, Sridhar R., Joshi, Hemant, Tirunagaru, Vijaya G., Gupta, Jang B.

Volltext

Abstract 1661: Development of lipid-based nanosuspension formulation of first-in-class PLK2 inhibitor GBO-006 to treat triple-negative breast cancer von Tirunagaru, Vijaya G., Roy Chowdhury, Arnab, Duraiswamy, Jeyaraj Athisayamani, Maddi, Srinivasa Rao, Mitra, Sayan, Deb, Chandra, Adluri, Ram Sudheer, Gupta, Jang B.

Volltext

INHIBITORS OF TRKA KINASE von TIRUNAGARU, Vijaya G, NAGASWAMY, Kumaragurubaran

Volltext bestellen

Inhibitors of TrkA kinase von Tirunagaru, Vijaya G, Nagaswamy, Kumaragurubaran

Volltext bestellen

Inhibitors of TrkA kinase von Tirunagaru, Vijaya G, Nagaswamy, Kumaragurubaran

Volltext bestellen